5CV — CureVac NV Cashflow Statement
0.000.00%
Last trade - 00:00- €486.29m
- €60.81m
- €70.87m
Annual cashflow statement for CureVac NV, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | fx Final | fx Final |
| Net Income/Starting Line | -83.9 | -112 | -148 | -488 | -262 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -6.95 | 22.9 | 45.8 | -414 | 71.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.03 | -16.2 | 687 | 18.2 | -135 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -87.4 | -97.3 | 595 | -867 | -301 |
| Capital Expenditures | -17.4 | -13.7 | -54 | -151 | -98 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 12.3 | 45.2 | 2.37 | 0 | -0.291 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -5.03 | 31.5 | -51.6 | -151 | -98.3 |
| Financing Cash Flow Items | — | — | — | — | 69.9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.132 | 76.1 | 934 | 408 | 66.4 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -92.3 | 10.4 | 1,472 | -604 | -332 |